S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:NTRA

Natera - NTRA Stock Forecast, Price & News

$56.65
+0.95 (+1.71%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$54.32
$56.72
50-Day Range
$39.72
$58.29
52-Week Range
$27.35
$59.75
Volume
917,175 shs
Average Volume
1.44 million shs
Market Capitalization
$6.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.27

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.0% Upside
$79.27 Price Target
Short Interest
Bearish
6.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Natera in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8.54 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.22) to ($2.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

397th out of 989 stocks

Medical Laboratories Industry

13th out of 26 stocks


NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Natera Third Quarter 2022 Earnings: Beats Expectations
Natera Reports Third Quarter 2022 Financial Results
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
2/28/2023
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.27
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+42.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-547,800,000.00
Pretax Margin
-66.67%

Debt

Sales & Book Value

Annual Sales
$820.22 million
Book Value
$7.23 per share

Miscellaneous

Free Float
101,652,000
Market Cap
$6.31 billion
Optionable
Optionable
Beta
1.20

Key Executives

  • Stephen Chapman
    President, Chief Executive Officer & Director
  • Robert A. SchuerenRobert A. Schueren
    Chief Operating Officer
  • Michael Burkes BrophyMichael Burkes Brophy
    Chief Financial & Accounting Officer
  • Eric A. Evans
    Chief Scientific Officer
  • Rishi Kacker
    Chief Technology Officer













NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price forecast for 2023?

6 brokerages have issued 12 month price objectives for Natera's shares. Their NTRA share price forecasts range from $65.00 to $100.00. On average, they expect the company's share price to reach $79.27 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2023?

Natera's stock was trading at $40.17 at the start of the year. Since then, NTRA stock has increased by 38.7% and is now trading at $55.70.
View the best growth stocks for 2023 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Tuesday, February, 28th. The medical research company reported ($1.37) EPS for the quarter, topping analysts' consensus estimates of ($1.40) by $0.03. The medical research company had revenue of $217.30 million for the quarter, compared to analysts' expectations of $215.50 million. Natera had a negative trailing twelve-month return on equity of 106.67% and a negative net margin of 66.79%. The business's revenue for the quarter was up 25.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.48) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $980.00M-$1.00 billion, compared to the consensus revenue estimate of $988.88 million.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of retail and institutional investors. Top institutional investors include Fred Alger Management LLC (9.19%), Norges Bank (2.85%), Eversept Partners LP (2.75%), Principal Financial Group Inc. (2.06%), Avidity Partners Management LP (1.84%) and Braidwell LP (1.66%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $55.70.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $6.31 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($5.57) on an earnings per share basis.

How many employees does Natera have?

The company employs 3,018 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 3/24/2023 by MarketBeat.com Staff